The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Sperizak 25 mg powder and solvent for prolonged-release suspension for injection



Accord Healthcare Ireland Ltd.PA2315/248/001

Main Information

Trade NameSperizak 25 mg powder and solvent for prolonged-release suspension for injection
Active SubstancesRisperidone
Dosage FormPowder and solvent for prolonged-release suspension for injection
Licence HolderAccord Healthcare Ireland Ltd.
Licence NumberPA2315/248/001

Group Information

ATC CodeN05AX08 risperidone

Status

License statusAuthorised
Licence Issued12/02/2021
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0012-022-065
Interchangeable List DocumentPDF of Interchangeable List
« Back